Long Cai is a Professor at the California Institute of Technology, affiliated with the Biology and Biological Engineering department. He pioneered the field of spatial genomics and co-developed transformative technologies such as seqFISH and MEMOIR. Research Interests: His work focuses on decoding biological systems through spatial genomics, integrating molecular imaging with computational analysis to uncover cellular organization in tissues. Key areas include developmental biology, neuroscience, kidney regeneration, and cancer biology. Publications: Recent studies highlight applications of spatial transcriptomics in kidney disease, brain nuclear architecture, and multi-omics tissue mapping. His research emphasizes creating high-resolution atlases of cellular dynamics. Scientific Awards: NIH Director’s Pioneer Award (2022) Labs & Collaborations: He leads the Cai Lab, which develops cutting-edge imaging tools in collaboration with the Elowitz Lab and other interdisciplinary teams.
Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.
Christopher E. Nelson is an Assistant Professor in the Department of Biomedical Engineering at the University of Arkansas, College of Engineering. His lab focuses on developing biologically inspired strategies for controlled drug and gene delivery, particularly in the context of gene therapy and regenerative medicine. He is actively supported by the NIH, DoD, and Arkansas Bioscience Institute. Education: Postdoctoral Fellow – Duke University Ph.D. – Vanderbilt University B.S. – University of Arkansas Research Focus: Dr. Nelson’s lab integrates genome editing technologies with targeted delivery systems to address challenges in treating genetic diseases and promoting tissue regeneration. Major themes include CRISPR/Cas9 delivery , gene regulation in wound healing , and safe-harbor genome integration in skeletal muscle. His work spans viral and non-viral delivery vehicles , including lipid nanoparticles and AAV vectors, with a strong emphasis on preclinical validation in models of Duchenne muscular dystrophy and inflammatory disease. Scientific Awards: Controlled Release Society Postdoctoral Fellowship The Hartwell Foundation Postdoctoral Fellowship NIH Pathway to Independence Award (K99/R00) Funding & Support: The Nelson Lab is currently funded by: NIH NIGMS R35 DoD CDMRP DMD IDEA Award Arkansas Bioscience Institute University of Arkansas Engineering & Honors Colleges Lab & Team: The Nelson Lab is a dynamic, interdisciplinary team working at the intersection of gene editing, biomaterials, and regenerative medicine. They regularly present at national conferences such as ASGCT and NCUR, and mentor undergraduate researchers through SURF and Honors College grants.
Brian Hie is an Assistant Professor of Chemical Engineering at Stanford University , a Dieter Schwarz Foundation Stanford Data Science Faculty Fellow , and an Innovation Investigator at Arc Institute . He leads the Laboratory of Evolutionary Design , focusing on the intersection of biology and machine learning . His prior roles include a Stanford Science Fellow in the Stanford University School of Medicine and a Visiting Researcher at Meta AI . Education: Ph.D. , Electrical Engineering and Computer Science , Massachusetts Institute of Technology (2021) Bachelor’s Degree , Stanford University Research Interests: Brian’s work bridges machine learning and computational biology , with a focus on protein engineering , single-cell RNA sequencing , and viral evolution . His Evolutionary velocity framework predicts protein evolutionary dynamics across timescales, while his Scanorama algorithm enables efficient integration of heterogeneous single-cell datasets. He also develops structure-informed language models for antibody optimization and uncertainty-aware ML for biological discovery. Publication Trends: His recent work (2023) emphasizes structure-based inverse folding for antibody evolution, evolutionary scale modeling , and unsupervised optimization . Earlier studies (2022-2021) cover evolutionary velocity , multi-modal single-cell analysis , and viral escape prediction using natural language analogies. Scientific Awards: Stanford Science Fellow (2021) National Defense Science and Engineering Graduate Fellowship (2019) Advising: He mentors doctoral students including Brandon Ameglio , Garyk Brixi , and Chang M. Yun , with a focus on biological design and computational methods . Labs & Collaborations: His lab collaborates with Bio-X and the Institute for Human-Centered Artificial Intelligence (HAI) , and he maintains affiliations with Sarafan ChEM-H and Stanford Data Science .
Dr. Anil Kumar is an Assistant Professor in the Department of Biochemistry, Microbiology & Immunology at the University of Saskatchewan's College of Medicine. He specializes in molecular virology, focusing on positive-stranded RNA viruses and their interactions with host immune systems. His research employs high-throughput genetic screens and reverse genetics systems to identify host factors critical for viral infection. Education includes a BSc in Agricultural Sciences (1999, Kerala Agricultural University), MSc in Plant Pathology (2001, Indian Agricultural Research Institute), and PhD in Molecular Virology (2010, University of Heidelberg). Postdoctoral training included stints at the University of Heidelberg (2010–2013) and the University of Alberta (2014–2020). Research interests center on Eastern Equine Encephalitis virus (EEEV) and Enterovirus D68 (EV-D68). For EEEV, his lab investigates immune evasion mechanisms and host-virus protein interactions to identify therapeutic targets. For EV-D68, they study CNS invasion mechanisms and novel host dependency factors linked to acute flaccid myelitis (AFM). Recent work includes studies on SARS-CoV-2, uncovering roles for host proteins like Argonaute 2 in viral restriction. His lab integrates molecular biology, virology, and systems biology approaches, with a focus on translational research for antiviral drug development. Collaborations include work on respiratory syncytial virus (RSV) entry mechanisms and dengue virus replication regulation.
Pablo Perez-Pinera is an Associate Professor in Biomedical and Translational Sciences at the Carle Illinois College of Medicine, University of Illinois. He leads the Genome Engineering and Transcriptional Regulation Laboratory, focusing on developing gene editing technologies for treating neurodegenerative and neuromuscular diseases. His research integrates cutting-edge genome engineering tools with innovative delivery systems to address previously incurable conditions. Dr. Perez-Pinera's research interests center on developing CRISPR-based genome editing technologies for therapeutic applications. His laboratory specializes in base editing approaches for exon skipping, particularly targeting diseases like Duchenne muscular dystrophy, Huntington's disease, Parkinson's disease, Alzheimer's disease, and ALS. His team develops novel delivery systems using AAV vectors to enable precise in vivo genome editing, with a particular focus on neurological and muscular disorders. The lab's work bridges fundamental molecular biology with translational applications, aiming to move promising technologies from bench to bedside. His laboratory has made significant contributions to the field of therapeutic genome editing, particularly in developing the SPLICER platform for efficient exon skipping through simultaneous splice site editing. His publications demonstrate expertise in base editing for neurodegenerative diseases, with multiple first-author and corresponding author papers in high-impact journals. His research has been supported by several NIH grants including R01 GM131272, UL1 TR001422, R01 GM141296, among others. Dr. Perez-Pinera actively mentors a diverse team of researchers including postdoctoral fellows, graduate students, and undergraduates. His laboratory includes researchers such as Devyani Swami (Postdoctoral Fellow), Michael Gapinske, Jackson Winter, Shraddha Shirguppe, Angelo Miskalis, and others who contribute to various aspects of genome engineering research. His grant funding supports both basic research on genome editing mechanisms and translational work toward therapeutic applications. The Genome Engineering and Transcriptional Regulation Laboratory maintains state-of-the-art facilities for molecular biology, cell culture, and in vivo studies. The team collaborates extensively with clinicians and researchers across the University of Illinois campus to translate genome editing discoveries into potential therapies for patients suffering from neurodegenerative and neuromuscular conditions.
Jessica Rosenholm is a Professor at the Faculty of Science and Engineering, Department of Pharmacy at Åbo Akademi University. Her research focuses on drug delivery systems, nanomedicine, and biomaterials engineering. She holds a D.Sc.(Tech.) and has authored over 200 publications. Key research areas include mesoporous silica nanoparticles, 3D bioprinting, and antimicrobial resistance solutions. Her work contributes to UN Sustainable Development Goals, particularly in advancing health technologies. Notable achievements include the Akzo Nobel Nordic Research Prize 2009 and the Knight, First Class, of the Order of the White Rose of Finland (2022). She leads projects like the MADNESS Centre of Excellence, exploring materials-driven solutions against antimicrobial resistance. Education: Doctor of Science (Technology) Research Interests: Nanoformulations, biomedical imaging, microfluidics, and tissue engineering. Recent articles highlight innovations in programmable nanocomposites for hearing loss treatment, microfluidic assembly of nanostructures, and 3D printing of drug delivery systems. Awards: ÅAU Chancellor’s Prize (2013), Forskarpriset ur Harry Elvings legat (2009) Grants: Projects funded by EU, Finnish Research Council, and Sigrid Jusélius Foundation. Labs/Teams: BioNanoMaterials group explores cutting-edge technologies like nanomedical agents and microfluidics. Current projects include the NAP4DIVE initiative for blood-brain barrier drug delivery.
Marjo Yliperttula is a Professor at the Department of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki. She serves as a supervisor in the Doctoral Programmes in Biomedicine, Drug Research, and Materials Research and Nanosciences, with expertise in biomaterials and pharmaceutical technology. Her research focuses on nanofibrillated cellulose (NFC) hydrogels for wound healing and drug delivery, extracellular vesicle (EV) engineering for therapeutic applications, and freeze-drying technologies for biomaterial preservation. Key contributions include NFC-based wound dressings that enhance platelet-rich plasma release (2024), Raman spectroscopy methods for monitoring freeze-drying-induced mutarotation (2024), and tandem chromatography techniques for high-purity EV isolation (2023). Her work bridges pharmaceutical sciences with regenerative medicine, emphasizing translational applications in chronic wound treatment and targeted drug delivery. Recent publications (2022-2025) reveal three dominant trends: (1) Optimization of NFC hydrogels for controlled drug release and tissue regeneration, (2) Advanced characterization of EV phenotypes under hypoxic conditions for improved therapeutic efficacy, and (3) Development of analytical methods (Raman spectroscopy, chromatography) to address manufacturing challenges in biopharmaceuticals. These themes reflect her group's commitment to solving critical problems in biomaterial stability, EV-based delivery, and precision wound care. Professor Yliperttula has supervised 10 doctoral theses, including recent work on NFC for skin substitutes (Elle Koivunotko), freeze-drying of hydrogels (Arto Merivaara), and mesenchymal stromal cells for wound healing (Jasmi Snirvi). She currently leads the Academy of Finland-funded GeneCellNa project (2024-2026) on gene/cell/nanotherapy for chronic diseases and a Finnish Red Cross project (2023-2024) on NFC for blood products, with cumulative project funding spanning 18 initiatives since 2005. She heads the Biopharmaceuticals Group within the Drug Research Program, fostering collaborations across pharmaceutical biosciences, materials science, and clinical medicine to advance next-generation therapeutic platforms.
Caryl E. Sortwell is a Professor of Translational Neuroscience and Edwin A. Brophy Endowed Chair in Central Nervous System Disorders at Michigan State University's College of Human Medicine. She leads the Sortwell Lab within the Neuroscience Program and Grand Rapids Research Center, focusing on Parkinson's disease (PD) therapeutics. Education : B.S. in Psychology/Pre-medicine (University of Illinois, 1987), Ph.D. in Anatomy and Cell Biology/Neurobiology (University of Illinois at Chicago, 1994) Positions : Assistant/Associate Professor at Rush University Medical Center (1997-2005), Associate Professor at University of Cincinnati (2005-2009), Professor at MSU College of Human Medicine (2009-present) Her research investigates alpha-synuclein pathology in PD using preformed fibril models to study neurodegeneration, neuroinflammation, and therapeutic interventions. She explores neurotrophic factors like BDNF, gene therapies targeting CaV1.3 channels, and deep brain stimulation mechanisms. Her work emphasizes precision medicine approaches to optimize treatment outcomes. Scientific contributions include methodological advancements in neurochemical sensing with diamond electrodes and viral vector delivery systems. Key collaborations include research with Dr. Joe Patterson on alpha-synuclein genetic consequences. Technical Expertise : Immunohistochemistry, stereotactic surgery, in vivo neurotoxicant models, protein analysis (Western blot/ELISA), droplet digital PCR, and neuroinflammatory profiling
Wen Xue is a Professor at UMass Chan Medical School, affiliated with the RNA Therapeutics Institute within the T.H. Chan School of Medicine. She holds multiple additional roles across departments such as the Program in Molecular Medicine, Cancer Biology, and Biochemistry and Molecular Biotechnology at the Morningside Graduate School of Biomedical Sciences. Her research focuses on developing genetic models for liver and lung cancer using CRISPR/Cas9 and RNAi tools. Key areas include CRISPR-mediated genome editing for cancer gene discovery, KRAS inhibition mechanisms, and miRNA networks in lung cancer. She has secured grants from NIH, American Cancer Society, and others. Awards include the NIH Director’s New Innovator Award and Lung Cancer Research Foundation grants. Her lab actively recruits postdoctoral researchers and offers rotation projects in CRISPR technology and cancer biology. Education: B.S. and M.S. in Biochemistry from Nanjing University; Ph.D. in Biochemistry from State University of New York, Stony Brook. Research Interests: Wen Xue’s lab employs CRISPR tools to accelerate cancer gene validation and therapeutic target identification. Projects include: CRISPR-based liver cancer gene correction and oncogene deletion studies. Investigating KRAS inhibition resistance via RNAi and CRISPR in lung cancer models. Characterizing miRNA networks using TCGA data to identify therapeutic miRNA candidates. Her work bridges functional genomics with precision medicine, emphasizing in vivo and in vitro platforms. Publications: Over 100 peer-reviewed articles, including high-impact studies on CRISPR applications in gene therapy and cancer modeling. Recent work explores prime editing, base editing, and viral/non-viral delivery systems for lung diseases. Grants & Awards: NIH grants (P01HL131471, DP2HL137167), American Cancer Society (RSG-16-093), and industry partnerships like the Cystic Fibrosis Foundation. Collaborations include projects on CFTR mutation repair and AAV vector development. Labs/Teams: Xue Lab focuses on cancer genetics and gene editing, with interdisciplinary collaborations in molecular medicine and bioengineering. Ongoing projects aim to translate CRISPR-based therapies into clinical applications.
Adam Caparco is the DiPietro Assistant Professor of Chemical Engineering at Northeastern University, with a 25% joint appointment in the Department of Chemistry and Chemical Biology. He leads the Caparco Research Group, focusing on agricultural and environmental biotechnology, enzyme immobilization, and protein assemblies. His work integrates plant virology, nanotechnology, and molecular engineering to address sustainability challenges in agriculture and environmental remediation. He is a member of the Institute for Plant-Human Interface and holds affiliations with Northeastern’s College of Engineering and School of Arts and Sciences. Education: B.S. in Chemical and Biomolecular Engineering from UCLA (2015), Ph.D. from Georgia Tech (2020) under Julie Champion and Andreas Bommarius, followed by a USDA NIFA Postdoctoral Fellowship at UC San Diego under Nicole Steinmetz. His research spans plant immunoengineering, biomanufacturing in plants, and protein-based nanomaterials for bioremediation. Research Interests Plant excretion pathways for pathogen defense and environmental remediation Design of immobilized enzymes for green chemical synthesis Plant virus nanoparticles for nucleic acid delivery and immunity modulation Multifunctional protein engineering for sustainable agriculture Recent articles highlight advancements in plant virus-based delivery systems, enzyme immobilization strategies, and nano-enabled precision agriculture. Awards include the USDA NIFA Postdoctoral Fellowship. Caparco advises graduate and undergraduate researchers, including Julia Hilgemberg Merlin (PhD ChE), Olha Bereziuk (PhD CCB), and Paul Carter (PhD ChE). He collaborates widely and seeks to expand interdisciplinary research in plant biotechnology. Labs/Teams: Caparco Research Group (EXP 420 lab, EXP 530B office) and the Institute for Plant-Human Interface.
Professor Ravi Shukla is a faculty member at RMIT University's School of Science, holding the title of Professor and Deputy Head of Department (Research). He specializes in Nanobiotechnology, with research spanning biomaterials, drug delivery systems, and medical diagnostics. His work integrates biosciences, materials science, and food technology to advance understanding of nanomaterial-biomolecular interactions. Academic History: Professor Shukla has held roles at RMIT since 2011, progressing from Research Fellow to his current professorship. He also serves as an Adjunct Professor at the University of Missouri and Theme Leader for Nanobiotechnology at RMIT’s Center for Advanced Materials and Industrial Chemistry. His teaching focuses on fostering student belonging and innovation in biotechnology education, including coordinating RMIT’s undergraduate Biotechnology program. Research Interests: His lab explores hybrid biomaterial synthesis, nano-enabled proteomics, and non-viral gene therapy using MOFs. Recent work emphasizes applications in diabetes biosensing, CRISPR/Cas9 delivery, and antimicrobial resistance mitigation through nanostrategies. Over 130+ publications and substantial research funding highlight his interdisciplinary impact. Professional Engagement: Editor roles in Frontiers in Bioengineering and Biotechnology , Co-Editor-in-Chief of Current Research in Nutrition and Food Science , and advisor to the Australasian Association of Ayurveda underscore his leadership. He actively mentors students in projects like nano-antimicrobial wound healing and aptamer-based hepatitis A detection. Key Achievements: Pioneered nucleic acid-encapsulated MOFs for cancer therapy and developed paper-based biosensors for rapid diagnostics. His work aligns with UN Sustainable Development Goals 2 (Zero Hunger) and 3 (Good Health).
Dr. Alexandra Piotrowski-Daspit is an Assistant Professor in the Biomedical Engineering department and Internal Medicine – Pulmonary and Critical Care Medicine at the University of Michigan Medical School. She is a chemical/biological engineer with expertise in polymeric biomaterials for gene therapies, focusing on in vivo behavior of delivery vehicles and strategies to optimize biodistribution. Education: Ph.D. in Chemical/Biological Engineering Her research bridges polymer chemistry, gene delivery, and translational medicine, emphasizing in utero interventions and pulmonary targeting. Key areas include nanoparticle surface engineering, macrophage decoys, and computational pharmacokinetic modeling. Recent publications highlight systemic in utero gene editing for cystic fibrosis, poly(amine-co-ester) nanoparticle tunability, and mucosal vaccination platforms. She also explores miRNA therapies for congenital diaphragmatic hernia and triplex-forming PNAs for CFTR correction. PhRMA Foundation Awardee (2024) Her work involves interdisciplinary collaborations, DEI initiatives, and translational projects from postdoc foundations in W. Mark Saltzman’s lab. Labs like Saltzman and SCGE teams support her research.
Guojun Chen is an Assistant Professor at the Department of Biomedical Engineering and a member of the Rosalind & Morris Goodman Cancer Institute (GCI) at McGill University . His research focuses on engineering intelligent biomaterials for precision medicine , with emphasis on non-viral genome editing , cold atmospheric plasma (CAP) therapy , and biomaterials-mediated immunotherapy . The lab operates in a multidisciplinary environment , integrating principles from materials science , chemistry , biology , and health sciences . Education : Ph.D. from University of Wisconsin-Madison (2017), Postdoc at UCLA (2020) Research Themes : Genome Editing Delivery : Designing non-viral vectors for efficient CRISPR/Cas9 delivery in vivo. CAP-mediated Immunotherapy : Developing portable cold plasma devices to synergize with immune checkpoint blockade and study CAP’s immunological mechanisms. Biomaterials-based Immunotherapy : Reprogramming tumor microenvironments using bioresponsive materials to enhance immune responses. Publication Trends : Recent work spans responsive nanomaterials , genomic editing systems , and plasma oncology , with a focus on cancer immunotherapy , diabetes diagnostics , and bioinspired medical devices . Scientific Awards : Canada Research Chair (2024, 2025) McGill's President's Prize for Emerging Researchers (2025) FRQS Chercheurs-boursiers (2022) Chinese Association for Biomaterials Young Investigator Award (2022) NSERC Discovery Grant (2021) Advising & Grants : Supervises 14 current graduate and undergraduate students. Secured $5M+ in funding from CIHR , NSERC , CCS , and CFI , including multi-institutional collaborations with Dr. Morag Park , Dr. Réjean Lapointe , and Dr. Ian Watson .
Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.
